Equities

Respiratorius AB (publ)

Respiratorius AB (publ)

Actions
Consumer DiscretionaryMedia
  • Price (SEK)0.0738
  • Today's Change-0.005 / -5.87%
  • Shares traded320.46k
  • 1 Year change-65.16%
  • Beta1.1385
Data delayed at least 15 minutes, as of Sep 13 2024 17:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Respiratorius AB (publ) is a Sweden-based biotechnology and pharmaceutical company. It develops candidate drugs for treatment of cancer, Chronic Obstructive Pulmonary Disease (COPD) and asthma. The project portfolio also includes development of a biomarker for cardiovascular positron-emission tomography (PET)-imaging. The oncology drug project VAL-001 aims for first-line treatment of Diffuse Large B-Cell Lymphoma (DLBCL). In the COPD and asthma projects, the Company develops two classes of drug substances, such as RESP-1000 and RESP-2000 series for bronchodilating effect on small airways. The Company’s primary markets are the United States and South Africa.

  • Revenue in SEK (TTM)1.35m
  • Net income in SEK-7.30m
  • Incorporated1998
  • Employees--
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Lidds AB0.00-25.60m18.97m1.00--2.46-----0.4664-0.46640.000.05660.00----0.00-97.07-46.33-111.99-51.61---1,934.24---3,076.68----0.1044---100.00---9.08------
Circio Holding ASA119.40k9.23m19.47m8.001.20--1.95163.070.68360.68360.0156-4.050.0043--0.014511,181.8233.11-46.58---53.40----7,730.08-6,902.00---------98.7735.4374.42------
Carbiotix AB (publ)1.83m-15.16m27.52m9.00--0.6377--15.01-17.61-17.611.4011.480.0694--16.79183,346.00-57.34-49.38-62.59-55.50157.27574.69-826.63-1,828.86---109.510.00--259.56-12.04-10.02--13.64--
Stayble Therapeutics AB0.00-20.40m28.64m2.00--2.34-----0.6413-0.64130.000.27950.00----0.00-81.91-78.64-93.24-95.58------------0.065------3.22------
SoftOx Solutions AS1.61m-58.81m33.34m7.00--0.2297--20.69-0.7729-0.77290.00220.07660.0166--0.493237,141.40-60.65-50.11-81.43-63.61-----3,649.40-639.340.4049-2.760.1463---1.8810.0644.55--39.43--
Scandion Oncology A/S0.00-54.53m33.86m4.00--0.725-----0.3727-0.37270.000.20140.00----0.00-72.35---84.88--------------0.0058------48.89------
ATTANA AB5.14m-12.18m35.31m10.00--2.18--6.87-0.0361-0.03610.01480.03760.1715-0.41271.97514,073.00-40.63-37.18-62.57-46.66127.26175.97-236.92-254.690.4858-4.430.158---32.896.615.80--8.21--
Peptonic Medical AB39.05m-45.25m35.68m37.00--0.1917--0.9138-0.025-0.0250.02220.03230.41851.425.491,055,432.00-48.49-46.02-61.53-60.8544.3454.26-115.88-139.380.5002-140.410.2084---14.93149.65-15.55--27.15--
Fluicell AB1.30m-27.16m37.36m11.00--1.73--28.81-0.1493-0.14930.00550.0450.05250.52651.9876,294.12-109.94-87.55-141.87-126.02-17.6672.97-2,094.37-650.233.83-695.510.00--2.6822.18-22.90------
Double Bond Phrmcutcl Intrntnl AB (publ)1.20m-16.75m37.57m10.00--10.10--31.30-0.18-0.180.01250.03510.0949--21.10120,004.00-132.48-80.90-176.94-106.45-344.65-1,073.66-1,395.47-1,360.031.12-1.360.00--10.25135.07-14.36------
Respiratorius AB (publ)1.35m-7.30m37.63m----0.9465--27.94-0.0229-0.02290.00420.0780.0461-------24.98---26.52--63.66---542.36------0.00-----------9.55--
Orphazyme A/S0.00-17.38m47.69m1.00--1.95-----325.75-325.750.00455.650.00----0.00-42.26-76.08-50.77-105.34------------0.00------32.00------
Combigene AB1.91m-36.52m49.90m10.00--0.5269--26.07-1.84-1.840.09674.780.0161--3.71239,265.00-30.66-13.00-32.33-14.58-----1,908.16-58.77----0.00---79.23268.58-479.27---24.02--
Nidhogg Resources Holding AB (publ)32.00k-4.21m54.09m3.00--59.38--1,690.42-0.0021-0.00210.000050.00050.0087--0.012810,666.67-114.92-70.56-204.32-82.81-25,093.75---13,156.25--------------77.06------
Data as of Sep 13 2024. Currency figures normalised to Respiratorius AB (publ)'s reporting currency: Swedish Krona SEK
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.